Tenaya Therapeutics, Inc.
TNYA
Rank in Stocks
#20518
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers,... Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Share Price
$0.2866
Last synced: 2026-11-20
Market Cap
$64.77M
Change (1 day)
-3.99%
Change (1 year)
-76.70%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Tenaya Therapeutics, Inc. (TNYA)
Category
Healthcare
EPS for Tenaya Therapeutics, Inc. (TNYA)
EPS as of September 2026 TTM: $-0.49
According to Tenaya Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-0.49. At the end of 2025 the company had an EPS of $-0.59, an increase over its 2024 EPS of $-1.31.
EPS history for Tenaya Therapeutics, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.49 | -16.95% |
| 2025 | $-0.59 | -54.96% |
| 2024 | $-1.31 | -22.02% |
| 2023 | $-1.68 | -39.13% |
| 2022 | $-2.76 | 63.31% |
| 2021 | $-1.69 | 81.72% |
| 2020 | $-0.93 | -2.11% |
| 2019 | $-0.95 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -3,295.92% |
US
|
|
| $-7.07 | 1,342.86% |
US
|
|
| $-5.29 | 979.59% |
AU
|
|
| $12.73 | -2,698.41% |
BE
|
|
| $21.56 | -4,500.00% |
NL
|
Questions about Tenaya Therapeutics, Inc.'s earnings per share (EPS)
What is Tenaya Therapeutics, Inc.'s earnings per share (EPS)?
Tenaya Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-0.49, as of Sep 2026.
What was Tenaya Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Tenaya Therapeutics, Inc.'s earnings per share (EPS) was $-0.59, compared with $-1.31 in 2024.
How has Tenaya Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Tenaya Therapeutics, Inc.'s earnings per share (EPS) was highest in 2025 ($-0.59) and lowest in 2022 ($-2.76).
How does Tenaya Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Tenaya Therapeutics, Inc.'s earnings per share (EPS) ($-0.49) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.